title: Complexities of adjuvant endocrine therapy in young premenopausal women.
abstract: Overall, this excellent overview of management issues for breast cancer patients under 40 years of age highlights the major questions surrounding choices of adjuvant systemic therapy. Treatment choices are dependent on breast cancer biology (receptor status) as well as patient factors (ovarian function and desire for future fertility). As many unanswered questions remain, it is important to continue to enroll subjects in clinical trials focused on this important patient population.
authors: Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Medical School, Ann Arbor, Michigan, USA.
authors: N Lynn
authors: NL
authors: Henry
authors: Jennifer J
authors: JJ
authors: Griggs
mesh_terms: D000328:Adult; D000568:Amenorrhea / Q000139:chemically induced; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics; D005260:Female; D005820:Genetic Testing; D005838:Genotype; D006801:Humans; D010053:Ovary / Q000187:drug effects; D017697:Premenopause; D020845:Selective Estrogen Receptor Modulators / Q000378:metabolism / Q000627:therapeutic use*; D013629:Tamoxifen / Q000378:metabolism / Q000627:therapeutic use*
chemical_list: D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen; D019389:Cytochrome P-450 CYP2D6